IBDEI2TO ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,45017,1,3,0)
;;=3^Postprocedure Hemorrhage of Skin/SQ Tissue After Derm Procedure
;;^UTILITY(U,$J,358.3,45017,1,4,0)
;;=4^L76.21
;;^UTILITY(U,$J,358.3,45017,2)
;;=^5009306
;;^UTILITY(U,$J,358.3,45018,0)
;;=L76.22^^170^2243^26
;;^UTILITY(U,$J,358.3,45018,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45018,1,3,0)
;;=3^Postprocedure Hemorrhage of Skin/SQ Tissue After Oth Procedure
;;^UTILITY(U,$J,358.3,45018,1,4,0)
;;=4^L76.22
;;^UTILITY(U,$J,358.3,45018,2)
;;=^5009307
;;^UTILITY(U,$J,358.3,45019,0)
;;=L41.9^^170^2243^3
;;^UTILITY(U,$J,358.3,45019,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45019,1,3,0)
;;=3^Parapsoriasis,Unspec
;;^UTILITY(U,$J,358.3,45019,1,4,0)
;;=4^L41.9
;;^UTILITY(U,$J,358.3,45019,2)
;;=^5009177
;;^UTILITY(U,$J,358.3,45020,0)
;;=L70.5^^170^2243^14
;;^UTILITY(U,$J,358.3,45020,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45020,1,3,0)
;;=3^Picker's Acne
;;^UTILITY(U,$J,358.3,45020,1,4,0)
;;=4^L70.5
;;^UTILITY(U,$J,358.3,45020,2)
;;=^5009272
;;^UTILITY(U,$J,358.3,45021,0)
;;=L81.9^^170^2243^15
;;^UTILITY(U,$J,358.3,45021,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45021,1,3,0)
;;=3^Pigmentation Disorder,Unspec
;;^UTILITY(U,$J,358.3,45021,1,4,0)
;;=4^L81.9
;;^UTILITY(U,$J,358.3,45021,2)
;;=^5009319
;;^UTILITY(U,$J,358.3,45022,0)
;;=L66.3^^170^2243^7
;;^UTILITY(U,$J,358.3,45022,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45022,1,3,0)
;;=3^Perifolliculitis Capitis Abscedens
;;^UTILITY(U,$J,358.3,45022,1,4,0)
;;=4^L66.3
;;^UTILITY(U,$J,358.3,45022,2)
;;=^5009255
;;^UTILITY(U,$J,358.3,45023,0)
;;=R23.3^^170^2243^13
;;^UTILITY(U,$J,358.3,45023,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45023,1,3,0)
;;=3^Petechiae
;;^UTILITY(U,$J,358.3,45023,1,4,0)
;;=4^R23.3
;;^UTILITY(U,$J,358.3,45023,2)
;;=^5019295
;;^UTILITY(U,$J,358.3,45024,0)
;;=D69.3^^170^2243^46
;;^UTILITY(U,$J,358.3,45024,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45024,1,3,0)
;;=3^Purpura Immune Hemorrhagic/Idopathic Thrombocytopenic
;;^UTILITY(U,$J,358.3,45024,1,4,0)
;;=4^D69.3
;;^UTILITY(U,$J,358.3,45024,2)
;;=^332746
;;^UTILITY(U,$J,358.3,45025,0)
;;=D69.2^^170^2243^47
;;^UTILITY(U,$J,358.3,45025,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45025,1,3,0)
;;=3^Purpura Simplex
;;^UTILITY(U,$J,358.3,45025,1,4,0)
;;=4^D69.2
;;^UTILITY(U,$J,358.3,45025,2)
;;=^5002366
;;^UTILITY(U,$J,358.3,45026,0)
;;=L76.31^^170^2243^23
;;^UTILITY(U,$J,358.3,45026,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45026,1,3,0)
;;=3^Postprocedure Hematoma of Skin/SQ After Derm Procedure
;;^UTILITY(U,$J,358.3,45026,1,4,0)
;;=4^L76.31
;;^UTILITY(U,$J,358.3,45026,2)
;;=^5138774
;;^UTILITY(U,$J,358.3,45027,0)
;;=L76.32^^170^2243^24
;;^UTILITY(U,$J,358.3,45027,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45027,1,3,0)
;;=3^Postprocedure Hematoma of Skin/SQ After Oth Procedure
;;^UTILITY(U,$J,358.3,45027,1,4,0)
;;=4^L76.32
;;^UTILITY(U,$J,358.3,45027,2)
;;=^5138775
;;^UTILITY(U,$J,358.3,45028,0)
;;=R73.03^^170^2243^27
;;^UTILITY(U,$J,358.3,45028,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45028,1,3,0)
;;=3^Pre-Diabetes
;;^UTILITY(U,$J,358.3,45028,1,4,0)
;;=4^R73.03
;;^UTILITY(U,$J,358.3,45028,2)
;;=^8295662
;;^UTILITY(U,$J,358.3,45029,0)
;;=L71.9^^170^2244^7
;;^UTILITY(U,$J,358.3,45029,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45029,1,3,0)
;;=3^Rosacea,Unspec
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2TO 3772 printed Oct 16, 2024@18:36:24 Page 2
IBDEI2TO ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,45017,1,3,0)
+2 ;;=3^Postprocedure Hemorrhage of Skin/SQ Tissue After Derm Procedure
+3 ;;^UTILITY(U,$J,358.3,45017,1,4,0)
+4 ;;=4^L76.21
+5 ;;^UTILITY(U,$J,358.3,45017,2)
+6 ;;=^5009306
+7 ;;^UTILITY(U,$J,358.3,45018,0)
+8 ;;=L76.22^^170^2243^26
+9 ;;^UTILITY(U,$J,358.3,45018,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,45018,1,3,0)
+12 ;;=3^Postprocedure Hemorrhage of Skin/SQ Tissue After Oth Procedure
+13 ;;^UTILITY(U,$J,358.3,45018,1,4,0)
+14 ;;=4^L76.22
+15 ;;^UTILITY(U,$J,358.3,45018,2)
+16 ;;=^5009307
+17 ;;^UTILITY(U,$J,358.3,45019,0)
+18 ;;=L41.9^^170^2243^3
+19 ;;^UTILITY(U,$J,358.3,45019,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,45019,1,3,0)
+22 ;;=3^Parapsoriasis,Unspec
+23 ;;^UTILITY(U,$J,358.3,45019,1,4,0)
+24 ;;=4^L41.9
+25 ;;^UTILITY(U,$J,358.3,45019,2)
+26 ;;=^5009177
+27 ;;^UTILITY(U,$J,358.3,45020,0)
+28 ;;=L70.5^^170^2243^14
+29 ;;^UTILITY(U,$J,358.3,45020,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,45020,1,3,0)
+32 ;;=3^Picker's Acne
+33 ;;^UTILITY(U,$J,358.3,45020,1,4,0)
+34 ;;=4^L70.5
+35 ;;^UTILITY(U,$J,358.3,45020,2)
+36 ;;=^5009272
+37 ;;^UTILITY(U,$J,358.3,45021,0)
+38 ;;=L81.9^^170^2243^15
+39 ;;^UTILITY(U,$J,358.3,45021,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,45021,1,3,0)
+42 ;;=3^Pigmentation Disorder,Unspec
+43 ;;^UTILITY(U,$J,358.3,45021,1,4,0)
+44 ;;=4^L81.9
+45 ;;^UTILITY(U,$J,358.3,45021,2)
+46 ;;=^5009319
+47 ;;^UTILITY(U,$J,358.3,45022,0)
+48 ;;=L66.3^^170^2243^7
+49 ;;^UTILITY(U,$J,358.3,45022,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,45022,1,3,0)
+52 ;;=3^Perifolliculitis Capitis Abscedens
+53 ;;^UTILITY(U,$J,358.3,45022,1,4,0)
+54 ;;=4^L66.3
+55 ;;^UTILITY(U,$J,358.3,45022,2)
+56 ;;=^5009255
+57 ;;^UTILITY(U,$J,358.3,45023,0)
+58 ;;=R23.3^^170^2243^13
+59 ;;^UTILITY(U,$J,358.3,45023,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,45023,1,3,0)
+62 ;;=3^Petechiae
+63 ;;^UTILITY(U,$J,358.3,45023,1,4,0)
+64 ;;=4^R23.3
+65 ;;^UTILITY(U,$J,358.3,45023,2)
+66 ;;=^5019295
+67 ;;^UTILITY(U,$J,358.3,45024,0)
+68 ;;=D69.3^^170^2243^46
+69 ;;^UTILITY(U,$J,358.3,45024,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,45024,1,3,0)
+72 ;;=3^Purpura Immune Hemorrhagic/Idopathic Thrombocytopenic
+73 ;;^UTILITY(U,$J,358.3,45024,1,4,0)
+74 ;;=4^D69.3
+75 ;;^UTILITY(U,$J,358.3,45024,2)
+76 ;;=^332746
+77 ;;^UTILITY(U,$J,358.3,45025,0)
+78 ;;=D69.2^^170^2243^47
+79 ;;^UTILITY(U,$J,358.3,45025,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,45025,1,3,0)
+82 ;;=3^Purpura Simplex
+83 ;;^UTILITY(U,$J,358.3,45025,1,4,0)
+84 ;;=4^D69.2
+85 ;;^UTILITY(U,$J,358.3,45025,2)
+86 ;;=^5002366
+87 ;;^UTILITY(U,$J,358.3,45026,0)
+88 ;;=L76.31^^170^2243^23
+89 ;;^UTILITY(U,$J,358.3,45026,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,45026,1,3,0)
+92 ;;=3^Postprocedure Hematoma of Skin/SQ After Derm Procedure
+93 ;;^UTILITY(U,$J,358.3,45026,1,4,0)
+94 ;;=4^L76.31
+95 ;;^UTILITY(U,$J,358.3,45026,2)
+96 ;;=^5138774
+97 ;;^UTILITY(U,$J,358.3,45027,0)
+98 ;;=L76.32^^170^2243^24
+99 ;;^UTILITY(U,$J,358.3,45027,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,45027,1,3,0)
+102 ;;=3^Postprocedure Hematoma of Skin/SQ After Oth Procedure
+103 ;;^UTILITY(U,$J,358.3,45027,1,4,0)
+104 ;;=4^L76.32
+105 ;;^UTILITY(U,$J,358.3,45027,2)
+106 ;;=^5138775
+107 ;;^UTILITY(U,$J,358.3,45028,0)
+108 ;;=R73.03^^170^2243^27
+109 ;;^UTILITY(U,$J,358.3,45028,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,45028,1,3,0)
+112 ;;=3^Pre-Diabetes
+113 ;;^UTILITY(U,$J,358.3,45028,1,4,0)
+114 ;;=4^R73.03
+115 ;;^UTILITY(U,$J,358.3,45028,2)
+116 ;;=^8295662
+117 ;;^UTILITY(U,$J,358.3,45029,0)
+118 ;;=L71.9^^170^2244^7
+119 ;;^UTILITY(U,$J,358.3,45029,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,45029,1,3,0)
+122 ;;=3^Rosacea,Unspec
